Merck & Company MRK

$132.47 -5.31 (-3.85%)

Valuation

Market cap
353,442,304,000
Revenue TTM
$65,011,000,000
Net income TTM
$18,254,000,000
P/E (trailing)
46.30
P/E (forward)
51.15
Profit margin
28.08%
Debt to equity
1.11

Trading

Volume
7,094,144
Avg volume
9,680,870
Day's range
$132.43 – $139.17
Shares out
2,465,246,000
Stochastic %K
8%
Beta
0.13
Analysts
Moderate Buy
Price target
$162.33

Price

Company profile

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. Th...

Show more

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
908 740 4000
Website
https://www.merck.com
Address
126 East Lincoln Avenue, Rahway, United States

Latest news

Stocktwits

CamRanhKid Nov 19, 7:16 PM
$MRK gap at 115.5. Buying target
0 replies
CamRanhKid Nov 19, 7:13 PM
$MRK $SPY drop it.
0 replies
CamRanhKid Nov 19, 6:32 PM
$MRK today conference was a joke
0 replies
CamRanhKid Nov 19, 6:22 PM
$MRK 2 abandoned studies. That is wasteful. Must buy out to recover
0 replies
CamRanhKid Nov 19, 6:08 PM
$MRK target buy 100
0 replies
CamRanhKid Nov 19, 6:03 PM
$MRK ceo on the way out. Bad news
0 replies
SellasGPS24BAT14 Nov 19, 5:12 PM
$INO $MRK $NVS CEO Dr. Shea already said on the earnings call and Jeffries conference that they are looking for partners but given $INO extremely low MC big pharmaceutical will buy the whole Co. $PGEN peek MC went to $3.2 Billion with an inferior treatment with multiple surgeries required throughout the cycle. $INO 0 surgeries during 5SECOND treatment Administration. Bidding war behind the scenes coming. Massive bids gobbling up any loose share from the weak hands. Entire $INO platform validated by FDA approval worth over $5 Billion + ✌️🙏❤️‍🩹
0 replies
CamRanhKid Nov 19, 5:07 PM
$MRK ceo leaving. Fill that gap
0 replies